References
- Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10(1):93. doi:10.1186/s13023-015-0310-1
- Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985;64(7):700–704.
- Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110(1):89–94. doi:10.1097/ALN.0b013e318190bb08
- Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology. 2008;108(4):603–611. doi:10.1097/ALN.0b013e318167aee2
- Wang YL, Guo XY, Luo AL. Malignant hyperthermia in Mainland China: an analysis of 34 cases. Chin J Anesthesiol. 2006;26(02):107–109.
- Tan L, Teng Y, Yu H, et al. Clinical features of suspected malignant hyperthermia in China from 2015 to 2020: a retrospective study from China malignant hyperthermia emergency assistance group. J Multidiscip Healthc. 2022;15:3005–3013. doi:10.2147/JMDH.S387208
- Task force on expert consensus on prevention and treatment of malignant hyperthermia in China. Expert consensus on prevention and treatment of malignant hyperthermia in China (2020 edition). Chin J Anesthesiol. 2021;41(01):20–25. doi:10.3760/cma.j.cn131073.20210102.00107
- Tan L, Yu H, Yan J, et al. The Knowledge profile, competence and pending problems of Chinese anesthesiologists in dealing with malignant hyperthermia: a cross-sectional survey. J Multidiscip Healthc. 2023;16:133–142. doi:10.2147/JMDH.S387025
- Gong X. Malignant hyperthermia when dantrolene is not readily available. BMC Anesthesiol. 2021;21(1):119. doi:10.1186/s12871-021-01328-3
- Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth. 2000;85(1):118–128. doi:10.1093/bja/85.1.118
- Sun J, Lyu S, Zhao R. Socioeconomic inequality in health outcomes among the elderly: evidence from a cross-sectional study in China. Risk Manag Healthc Policy. 2020;13:397–407. doi:10.2147/RMHP.S248019
- Larach MG, Klumpner TT, Brandom BW, et al. Succinylcholine use and dantrolene availability for malignant hyperthermia treatment: database analyses and systematic review. Anesthesiology. 2019;130(1):41–54. doi:10.1097/ALN.0000000000002490
- Li Z, Liu K, Guo X. Dantrolene available in China for malignant hyperthermia treatment. Anesthesiology. 2022;136(3):515–516. doi:10.1097/ALN.0000000000003998
- Aderibigbe T, Lang BH, Rosenberg H, Chen Q, Li G. Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia. Anesthesiology. 2014;120(6):1333–1338. doi:10.1097/ALN.0000000000000257
- Ho PT, Carvalho B, Sun EC, Macario A, Riley ET. Cost-benefit analysis of maintaining a fully stocked malignant hyperthermia cart versus an initial dantrolene treatment dose for maternity units. Anesthesiology. 2018;129(2):249–259. doi:10.1097/ALN.0000000000002231
- Zhang C, Wang S, Li H, et al. Anaesthesiology in China: a cross-sectional survey of the current status of anaesthesiology departments. Lancet Reg Health West Pac. 2021;12:100166. doi:10.1016/j.lanwpc.2021.100166